BSD Medical Expands Distribution Network to Fully Cover Entire United States
October 15 2014 - 9:15AM
Business Wire
Signs Distribution Agreement with KOL
Bio-Medical Instruments, Inc.
BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”),
a leading provider of medical systems that treat cancer and benign
diseases using heat therapy, announced today that the company has
signed an agreement with KOL Bio-Medical Instruments, Inc. (KOL)
for the sales and distribution of BSD’s MicroThermX® Microwave
Ablation (MicroThermX) line of products. KOL sales and distribution
area will include up to 15 states in the Northeast, Mid-Atlantic
and Southeast.
“This agreement with KOL fully expands our distribution network
across the United States to include key states on the eastern
seaboard, from Maine to Florida,” said Brian Ferrand, BSD Vice
President of Domestic Sales. “KOL is a well-respected distributor
that has solid and extensive relationships with interventional
radiologists throughout the Eastern United States. Moreover,
between our carefully selected mix of distributors and direct sales
representatives, we now have full sales coverage throughout the
entire United States. This should drive even greater recognition
and adoption of our microwave ablation products in the marketplace
and make us extremely accessible and responsive to our
customers.”
Headquartered in Virginia, KOL is a Service Disabled Veteran
Owned specialty distributor that has an extensive 40-plus year
history of selling and distributing emerging medical technologies.
For the past 40-years, KOL’s highly trained and experienced sales
force has helped pioneer and introduce advanced medical devices to
hospitals and clinicians throughout the Eastern United States.
About the MicroThermX® Microwave Ablation
System
The MicroThermX is a compact, mobile, state-of-the-art,
proprietary system that includes a microwave generator,
single-patient-use disposable antennas, and a thermistor-based
temperature monitoring system. The innovative design of the
MicroThermX is the first of its kind that allows delivery of higher
power levels using a single generator.
The MicroThermX utilizes innovative synchronous phased array
technology that was developed and patented by MicroThermX BSD to
provide a wide range of uniform zones of ablation. The MicroThermX
includes innovative, high-end disposables (SynchroWave antennas)
that are used in each ablation treatment and will provide a
significant ongoing revenue stream.
The soft tissue (tumor) ablation world market potential is
estimated to exceed $2.3 billion. The U.S. Food and Drug
Administration (FDA) has granted the Company a 510(k) clearance to
market the MicroThermX for ablation of soft tissue. BSD has also
received CE Marking for the MicroThermX System, which allows BSD to
market the MicroThermX in Europe. CE Marking is also recognized in
many countries outside of the EU, providing BSD the ability to
market the MicroThermX to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy delivered using focused microwave energy and radiofrequency
(RF). BSD’s product lines include ablation and hyperthermia
treatment systems. BSD’s microwave ablation system has been
developed as a stand-alone therapy to ablate and destroy soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market, and well established distribution
in the United States, Europe and Asia. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors
with heat (hyperthermia) while increasing the effectiveness of
other therapies such as radiation therapy. Certain of the Company’s
products have received regulatory approvals in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our 2014 plans,
are forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. All forward-looking
statements are subject to risks and uncertainties detailed in the
Company's filings with the Securities and Exchange Commission,
including the market demand for our MicroThermX® products and the
regulatory requirements we face. These forward-looking statements
speak only as of the date on which such statements are made, and
the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date, except as
required by law.
for BSD Medical CorporationTricia Ross,
310-622-8226investor@bsdmc.com